Diffuse Large B Cell Lymphoma
Conditions
Keywords
Decitabine, ORR, TTP, OS, PFS
Brief summary
To explore the safety, tolerability and clinical effects of decitabine combined with R±DHAP for patients with replase and refractory Diffuse Large B cell lymphoma.
Detailed description
This is a randomized,controlled,prospective,open,multi-center clinical trial,amied to evaluate the safety, tolerability,and efficacy of decitabine combined with R±DHAP in replase and refractory Diffuse Large B cell lymphoma.A total of 60 patients are planned to be enrolled into the study.Patients with diagnosis of replase and refractory Diffuse Large B cell lymphoma will be into two groups,and be treated with decitabine pluse R±DHAP or only R±DHAP,respectively.The primary end points are objective responder rate(ORR) and time to progression(TTP) and the secondary end points include overall survival(OS) and progression free survival(PFS).
Interventions
DRUGDecitabine
Given ivgtt
Sponsors
Mingzhi Zhang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* age:14-65 years;ECOG rate≤2;expected survival≥3 months * patients with Diffuse Large B cell lymphoma diagnoesd by histopathology detection; * patients ever received RCHOP or CHOP chemotherapy but did not receive DHAP * patients never received radiotherapy * patients with no chemotherapy contraindications:hemoglobin ≥ 90g/L,absoluate neutrophil count ≥1.5x109/L,blood platelet ≥100x109/L,ALT and AST ≤ 2-fold upper normal limit,serum bilirubin ≤1.5-fold upper normal limit,serum creatinine ≤1.5-fold upper normal limit,serum albumin ≥ 30g/L,normal serofibrinogen; * at least one measurable nidus; * no other severe diseases conflict with this project,cardiopulmonary function is basically normal * the urine or blood pregnancy test of women in childbearing age must be negative in 7 days before follow-up visit; * applicable for follow-up visit; * no other antitumor adjoint therapy(including antitumor Chinese medicine,immunotherapy and biotherapy),but double phosphate anti-bone transfer therapy and other symptomatic treatment are acceptable; * understanding this study and assigning informed consent.
Exclusion criteria
* rejecting providing blood preparation; * allergic to drug in this study and with metabolic block; * rejecting adopting reliable contraceptive method in pregnancy or lactation period; * uncontrolled internal medicine disease(including uncontrolled diabetes,severe incompetence cardiac,lung,liver and pancreas）； * with severe infection; * with primary or secondary central nervous system tumor invasion; * with immunotherapy or radiotherapy contraindication; * ever suffered with malignant tumor; * having peripheral nervous system disorder or dysphrenia; * with no legal capacity,medical or ethical reasons affecting research proceeding; * participating other clinical trials simultaneously; * adopting other anti-tumor medicine excluding this research; * the researchers considering it inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | up to 2 months | Objective Responder Rate |
| TTP | up to 2 months | Time TO Progression |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | up to 2 months | Overall Survival |
| PFS | up to 2 months | Progression Free Survival |
Countries
China
Contacts
Primary ContactMingzhi Zhang, Pro,Dr
Backup ContactMingzhi Zhang
Outcome results
None listed